65岁以上感染HIV女性宫颈及阴道细胞学异常的发生率
该回顾性队列纳入2000至2018年在休斯顿一家县医院系统接受妇科随访的69例65岁以上、无宫颈细胞学异常史的HIV感染女性,12例(17%)在65岁后出现细胞学异常,其中3例(4%)为高级别鳞状上皮内病变,发病率为3.5例/100人年(95%CI 1.58–7.81)。作者据此同意现行建议,即HIV感染女性65岁后继续常规巴氏涂片筛查,但需更大样本研究进一步巩固证据。
要点
- 69例65岁以上无细胞学异常史的HIV感染女性中,12例(17%)出现细胞学异常,3例(4%)为高级别鳞状上皮内病变。
- 异常细胞学发病率为3.5例/100人年(95%CI 1.58–7.81),无女性进展为浸润癌。
- HIV诊断时或细胞学时CD4计数<200与巴氏涂片异常相关(P<.0001,P=.031)。
核心结论
- 基于研究期间4%的高级别鳞状上皮内病变/宫颈上皮内瘤变2+/阴道上皮内瘤变2+比例,作者同意现行建议,即HIV感染女性65岁后继续常规巴氏涂片筛查。
- 作者认为需要更大规模研究提供更多证据,以巩固这一特殊且不断增长人群的循证筛查建议。
研究设计与样本
- 回顾性病历审查,纳入2000至2018年在德克萨斯州休斯顿一家县医院系统接受妇科随访的69例65岁以上、无宫颈细胞学异常史的HIV感染女性。
- 分析65岁后所有可获得的细胞学结果以确定异常细胞学发生率,并分析人口学与临床危险因素(含HIV特异性因素)及匹配的宫颈和阴道病理结果。
- 统计分析使用Stata 15,分类变量采用χ2检验、连续变量采用Wilcoxon秩和检验;采用Kaplan-Meier法估算发生异常细胞学结果的累积概率。
主要发现
- 69例无宫颈细胞学异常史的女性中,12例(17%)随后出现细胞学异常,其中3例(4%)为高级别鳞状上皮内病变。
- 异常细胞学发病率为3.5例/100人年(95%CI 1.58–7.81)。
- 无人口学或妇科特征与异常细胞学相关。
- HIV诊断时CD4计数<200与巴氏涂片异常相关(P<.0001),细胞学时CD4计数<200与巴氏涂片异常相关(P=.031)。
- 县医院系统内有病理结果的8例女性中,4例(50%)为宫颈上皮内瘤变2+或阴道上皮内瘤变2+;无女性发生浸润癌。
关键数值与推荐
- 异常细胞学发病率:3.5例/100人年(95%CI 1.58–7.81)。
- HIV诊断时CD4计数<200与巴氏涂片异常相关(P<.0001)。
- 细胞学时CD4计数<200与巴氏涂片异常相关(P=.031)。
- 有病理结果的8例中,4例(50%)为宫颈上皮内瘤变2+或阴道上皮内瘤变2+。
临床怎么用
- 作者同意现行建议,即HIV感染女性65岁后继续常规巴氏涂片筛查。
- 作者认为需要更大规模研究提供更多证据,以巩固该人群的循证筛查建议。
局限性
- 本研究为回顾性病历审查。
- 研究期间巴氏涂片异常的女性中50%失访,这些患者结局未知。
- 作者认为需要更大规模研究提供更多证据,以巩固该人群的循证筛查建议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Women with human immunodeficiency virus have higher rates of abnormal cervical and vaginal cytology and, subsequently, of cervical and vaginal cancers. Although professional bodies currently advocate for indefinite cytology screening for women living with human immunodeficiency virus, these recommendations are based on expert opinion, not evidence-based. In the general population, women who have never had an abnormal cytology result can cease screening at age 65 years. This is due to the relatively low incidence of dysplasia in this group and the risk of false-positive results as women age, invasive follow-up testing, and destructive treatments of lesions that are unlikely to progress to cancer. What is unclear, however, is how human immunodeficiency virus-infected women over age 65 years who have no history of abnormal cytology should be screened to maximize benefit while reducing harms of overscreening. This is a crucial question, as women over age 65 years who are living with human immunodeficiency virus comprise a rapidly growing population. OBJECTIVE: To describe the incidence of abnormal cervical and vaginal cytology results in women over the age of 65 years living with human immunodeficiency virus, with the goal of providing evidence for screening recommendations. MATERIALS AND METHODS: A retrospective chart review was performed, identifying 69 women who received gynecologic follow-up in a county hospital system in Houston, Texas, between 2000 and 2018 and who met study criteria. Incidence of abnormal cytology after age 65 was determined by analyzing all available cytology results after age 65. Demographic and clinical risk factors, including human immunodeficiency virus-specific clinical risk factors, were analyzed. Matched cervical and vaginal pathology results, if conducted, were also evaluated. Statistical analyses were conducted using Stata 15, including χ2 tests and Wilcoxon rank-sum tests for categorical and continuous variables, respectively. Estimates of the cumulative probability of developing an abnormal cytology result was calculated using the Kaplan-Meier method. RESULTS: Among 69 women with no history of abnormal cervical cytology, 12 (17%) went on to develop abnormal cytology results, including 3 (4%) showing high-grade squamous intraepithelial lesions. The incidence rate was 3.5 cases per 100 woman-years (95% confidence interval, 1.58, 7.81). No demographic or gynecologic characteristics were associated with abnormal cytology. A CD4 count of <200 at the time of human immunodeficiency virus diagnosis or at the time of cytology was associated with an abnormal Papanicolaou test result (P < .0001, P = .031). Of women with pathology results in the county hospital system (n = 8), 4 (50%) had cervical intraepithelial neoplasia 2+ or vaginal intraepithelial neoplasia 2+. No women developed invasive cancer. However, 50% of women who had an abnormal Papanicolaou test result in the study period were lost to follow-up; outcomes for these patients are unknown. CONCLUSION: Given the relatively high proportion (4%) of women with high-grade squamous intraepithelial lesions/cervical intraepithelial neoplasia 2+/vaginal intraepithelial neoplasia 2+ during the study period, we agree with current screening recommendations for continued routine Papanicolaou testing after the age of 65 years in women with human immunodeficiency virus. More evidence from larger studies is needed to solidify evidence-based screening recommendations in this unique and growing population.
引用
- Stewart KA, Allen SM, Chesnokova AE, et al. Incidence of abnormal cervical and vaginal cytology among women over age 65 years living with human immunodeficiency virus. Am J Obstet Gynecol. 2019. PMID: 31678094. doi:10.1016/j.ajog.2019.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。